[Extramedullary IgD lambda plasmacytoma mimicking a pituitary chromophobe adenoma].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Otero.
Explore the source record for details and available documents.
Cyclophosphamide was administered to 42 patients with acute lymphocytic leukemia (ALL) as a daily continuous iv infusion at a dose of 400 mg/m2/day x 5 days; the courses of treatment were repeated every 3 weeks. Of the 42 patients entered, 21 achieved a complete response, two achieved a partial response, 12 failed to respond, and seven were considered to have early deaths. The response rate was 69.5% if only patients who received adequate trials are considered; mean duration of response was 18.5 weeks and mean survival time was 24.2 weeks. Twenty-three patients had relapsed after previous chemotherapy, and 19 patients were untreated for advanced high-risk cases of ALL; no difference was found in the response rates, durations of response, and survival times between these groups. No significant genitourinary toxicity occurred. Myelosuppression became the dose-limiting toxic effect. Continuous infusion of cyclophosphamide is a clinically effective method of ALL treatment and may have a role in the initial combination regimens for this hematologic malignancy.
17 cases of Hodgkin's disease are reported, seen in a ten year period. Age of patients oscillated between three and seven years. There was a predominance of mixed cellularity type in histologic pattern. Most of patients were diagnosed in advanced clinical stages. Primary sign of disease was presence of cervical adenopathies and there were few cases of thoracic disease. Treatment consisted in radiotherapy and chemotherapy, according to histological type and clinical stage. Survival in our serie is of 53.3% with periods of observation from six months to seven years.